Tonix Pharma (TNXP) Misses Q4 EPS by 79c

Tonix Pharma (NASDAQ: TNXP) reported Q4 EPS of ($3.98), $0.79 worse than the analyst estimate of ($3.19). Revenue for the quarter came in at $5.39 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on Tonix Pharma (TNXP) click here.

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Jefferies Downgrades Pop Mart International Group Ltd (9992:HK) to Hold
• Holcim to acquire Fermacell from James Hardie for EUR 840M